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Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) is an important nosocomial and 
community pathogen. The objectives of this study were to estimate the prevalence of multidrug-
resistant MRSA strains in clinical specimens and to investigate the sensitivity pattern of these 
strains against various antibiotics used for treating hospitalized and out patients. Strains were 
identiﬁ  ed using standard procedures, and their sensitivity pattern was investigated using such 
techniques as disc diffusion, minimum inhibitory concentration (MIC), and the mecA gene 
PCR. Among 783 isolates of S. aureus, 301 (38.44%) were methicillin-resistant, of which 
217 (72.1%) were found to be multidrug-resistant. Almost all MRSA strains were resistant to 
penicillin, 95.68% were resistant to cotrimoxazole, 92.36% were resistant to chloramphenicol, 
90.7% were resistant to norﬂ  oxacin, 76.1% were resistant to tetracycline, and 75.75% were 
resistant to ciproﬂ  oxacin. Vancomycin was the most effective drug, with only 0.33% of MRSA 
strains being resistant to it. It is concluded that antibiotics other than vancomycin can be used 
as anti-MRSA agents after a sensitivity test so as to preclude the emergence of resistance to it 
and that prevailing problems in chemotherapy will escalate unless indiscriminate and irrational 
usage of antibiotics is checked.
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Introduction
Infections caused by Staphylococcus aureus have a poorer prognosis when the infecting 
strain is MRSA (Cosgrove et al 2003). Since its ﬁ  rst report in 1961 (Jevons 1961), the 
strain has been progressively causing increased mortality, morbidity, and health care 
costs with skin and soft tissue infections, ventilator-associated pneumonia, catheter 
associated bacteremia, and many other infections in hospitals and communities. First 
detected in hospitals, methicillin resistance is now increasingly recognized in the 
community (Chambers 2001).
In addition to dire consequences of infections, MRSA strains are important for their 
resistance to many other commonly used antibiotics and the emergence of resistance 
to vancomycin, the drug that has been used to treat MRSA infections for more than 
three decades. Thus, it is immensely important to study the antibiogram of MRSA in 
a given hospital so that the results of such studies can be exploited to minimize the 
irrational use of vancomycin when other antibiotics would cure an infection. Reports 
of emergence of vancomycin resistance in S. aureus from India (Assadullah et al 2003; 
Tiwari and Sen 2006; Saha et al 2008) further justify this necessity.
The prevalence of MRSA has varied from hospital to hospital in various countries. 
About 40% of S. aureus infections acquired in large US hospitals (500 or more beds) 
are methicillin-resistant (Red Book 2003). Prevalence is constantly soaring in many 
countries, and in some hospitals, more than half of all S. aureus disease isolates are 
MRSA (Voss and Doebbeling 1995). In many American and European hospitals, the 
percentage of MRSA has ranged from 29% to 35% of all clinical isolates. Meanwhile, Infection and Drug Resistance 2008:1 58
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information from developing countries is provided only 
by relatively sophisticated hospitals (Degerli et al 2000; 
Gastmeier et al 2000; Santos et al 2000); as a consequence, 
the data on MRSA prevalence, most of which are from 
developed countries, are inadequate in estimating the overall 
global distribution (Pulimood et al 1996; Verma et al 2000; 
Majumder et al 2001; Tahnkiwale et al 2002; Anupurba et al 
2003; Mohanty et al 2004; Rajaduraipandi et al 2006; Mehta 
et al 2007; Mulla et al 2007).
The present study uncovers the prevalence of multidrug-
resistant MRSA strains and investigates their antibiotic sen-
sitivity pattern in a tertiary care hospital of northern India.
Material and methods
During August 2002 and June 2006, a total of 783 strains of 
S. aureus were isolated from various specimens of different 
patients visiting and admitted at Sir Sundar Lal Hospital, 
a 972 bed tertiary care teaching hospital of Banaras Hindu 
University at Varanasi, India.
Isolation and identiﬁ  cation 
of staphylococci from clinical specimens
All specimens, except urine for which cystine lactose elec-
trolyte deﬁ  cient agar (HiMedia, New Delhi, India) was used, 
were cultured on blood agar and MacConkey agar (HiMedia, 
New Delhi, India).  S. aureus was identiﬁ  ed and differentiated 
from related organisms on the basis of colony morphology, 
Gram staining, catalase test, tube coagulase test using rabbit 
plasma, slidex staph plus (Biomerurix India Ltd, New Delhi, 
India), thermonuclease and acetoin production, and mannitol 
fermentation (Barid 1996). Using growth on blood agar, all 
the strains were subjected to the following tests. S. aureus 
ATCC 25923 (mecA negative) and ATCC 43300 (mecA posi-
tive) were used for the quality control of all the tests.
Disc diffusion test by Kirby–Bauer 
method
Mueller–Hinton agar (MHA) plates were overlaid with the 
saline suspension of a strain (turbidity matching 0.5 McFarland 
standard), and the following antibiotic discs procured 
from HiMedia, India were placed on the plate after 10 minutes, 
with six discs on a plate: penicillin (10 U), oxacillin 
(1 μg), gentamicin (10 μg), tobramycin (30 μg), amikacin 
(30 μg), netilmicin (30 μg), norfloxacin (10 μg), cipro-
floxacin (5 μg), chloramphenicol (30 μg), erythromycin 
(15 μg), tetracycline (15 μg), trimethoprim/sulfamethoxazole 
(1.25/23.75 μg), nitrofurantoin (300 μg), vancomycin (30 μg), 
and sulbactam/cefoperazone (30/75 μg). After 24 and 48 h of 
incubation at 35 °C, the plates were read using the NCCLS 
break-points as reference (NCCLS 2004).
Oxacillin MIC test
Gradient plates of MHA containing 2% NaCl were prepared 
with doubling dilutions (from 0.25 μg/ml to 256 μg/ml) of 
oxacillin. Inoculum was prepared by diluting 0.5 McFarland 
equivalent suspension of a strain with sterile normal saline 
to the concentration of 104 CFU/ml. The plates were spot-
inoculated and incubated at 35 °C for 24 h. An oxacillin 
minimum inhibitory concentration (MIC) of 2 μg/ml 
indicated that the strain was susceptible and that of 2 μg/ml 
resistant (NCCLS 2003).
The mecA gene detection by PCR
Staphylococcal DNA was isolated using chloroform: phenol 
extraction method (Sambrook et al 1989). The primers used for 
detection of the mecA gene were MecA1 (5’-GTA GAA ATG 
ACT GAA CGT CCG ATA A) and MecA2 (5’-CCA ATT 
CCA CAT TGT TTC GGT CTA A), as described earlier (Geha 
et al 1994). A Biometra DNA thermocycler was programmed 
for initial denaturation at 94 °C for 4 min; 30 cycles of ampliﬁ  -
cation (denaturation at 94 °C for 45 sec, annealing at 56 °C for 
45 sec, and extension at 72 °C for 30 sec); and a ﬁ  nal extension 
at 72 °C for 2 min. To visualize, 10 μl of the PCR amplicon was 
loaded in 2% agarose gel in TBE (0.089 M Tris, 0.089 M boric 
acid, 0.002 M EDTA) containing 0.5 μl/ml of ethidium bromide 
and visualized by using UV transillumination at 300 nm. DNA 
fragments of 310 bp corresponded to the mecA gene.
Results
Of the 783 S. aureus strains (503 from outpatient departments 
[OPDs] and 280 from wards), 301 (38.44%)   – 187 from 
OPDs and 114 from wards – showed methicillin resistance in 
disc diffusion and MIC tests and were conﬁ  rmed as MRSA 
by the mecA gene PCR. The remaining 482 (61.56%) were 
MSSA. Table 1 shows the pattern of resistance shown by 
MRSA strains as well as compares its distribution in OPDs 
and wards. Resistance to penicillin was highest (97%) 
followed by cotrimoxazole (95.68%), chloramphenicol 
(92.36%), and norﬂ  oxacin (90.7%).
The resistance pattern of MRSA was somewhat varying 
between OPDs and wards for macrolides, chloramphenicol, 
tetracycline, cotrimoxazole, nitrofurantoin and betalactam/
betalactamase inhibitor combination; the pattern was more 
or less same for other antibiotics (Table 1).
Out of 301 MRSA isolates, 217 (72.1%) were multidrug 
resistant, with 136 being resistant to more than three Infection and Drug Resistance 2008:1 59
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antimicrobials except vancomycin. One MRSA strain was 
found to be resistant to all antibiotics including vancomycin 
(Table 2).
Frequency of isolating MRSA was maximum in cutaneous 
and wound specimens (42.2%) followed by blood, respiratory 
specimens, and urine (Table 3).
Discussion
Studies show that the epidemiology of MRSA over different 
parts of India is not uniform. The present study reports 
38.44% MRSA among S. aureus isolates, whereas an 
earlier study done in the same hospital here had shown a 
higher prevalence of 54.8% (Anupurba et al 2003). Some 
studies have reported comparable prevalence: 38.56% in 
Delhi (Mohanty et al 2004), 31.1% in a multicenter study 
in Tamilnadu (Rajaduraipandi et al 2006), and 39.50% in 
South Gujarat (Mulla et al 2007). In contrast, other studies 
have reported entirely different prevalence: 24% in Vellore 
(Pulimood et al 1996), 80.89% in Indore (Verma et al 2000), 
52.9% in Assam (Assadullah et al 2003), 19.56% in Nagpur 
(Tahnkiwale et al 2002), and 24% in Chandhigarh (Mehta 
et al 2007). Although it’s extremely difﬁ  cult to explain these 
conﬂ  icting data with regards to both time and place of study, 
the variation is probably due to differential clonal expansion 
and drug pressure in community.
Given the fact that staphylococci spread by direct or indirect 
person-to-person contact, the emergence of multidrug-resistant 
stains of MRSA is worrisome in the present therapeutic 
scenario. Multidrug resistance was deﬁ  ned as resistance of a 
MRSA strain towards three or more antibiotics at a given point 
of time. In the USA, some workers (Styers et al 2006) have 
reported multi-drug resistance rates of 67.8% (for inpatients) 
and 65% (for outpatients) in lower respiratory tract MRSA 
isolates. In Nigerian women, a total of 43 S. aureus out of 60 
were found to be multidrug resistant (Onanuga et al 2005). 
We found a high percentage of multidrug-resistant MRSA 
(72.1%) in our hospital. If we look into the Indian literature, 
it seems the burden of multi drugresistant-MRSA is increas-
ing over time: for instance, 23.2% was reported by Majumder 
and colleagues in 2001; 32% by Anupurva and colleagues in 
2003; and 63.6% by Rajaduraipandi and colleagues 2006. The 
lesson is clear: MRSA surveillance and strict drug policy are 
of paramount importance, or else the threat will increase.
Table 1 Resistance pattern of MRSA against various antimicrobials and its relative distribution in OPDs and wards
Antimicrobials Overall resistance 
(n = 301)
Resistance in 
OPDs (n = 187)
Resistance in 
wards (n = 114)
Penicillin 97% (292) 96.79% (181) 97.37% (111)
Gentamicin 55.81% (168) 55.6% (104) 56.14% (64)
Tobramycin 53.49% (161) 54.01% (101) 52.63% (60)
Amikacin 41.53% (125) 40.64% (76) 42.98% (49)
Netilmicin 65.78% (198) 65.24% (122) 66.67% (76)
Norﬂ  oxacina 90.7% (273) 90.91% (170) 90.35% (103)
Ciproﬂ  oxacin 75.75% (228) 76.47% (143) 75.56% (85)
Chloramphenicol 92.36% (278) 90.91% (170) 94.74% (108)
Erythromycin 68.77% (207) 66.31% (124) 72.81% (83)
Tetracycline 76.1% (229) 73.79% (138) 79.82% (91)
Trimethoprim/Sulphamethoxazole 95.68% (288) 94.12% (176) 98.25% (112)
Nitrofurantoina 58.14% (175) 60.43% (113) 54.4% (62)
Vancomycin 0.33% (1) 0% 0.88% (1)
Cefoperazone/Sulbactam 65.12% (196) 67.91% (127) 60.53% (69)
Note: aTest done only for urine isolates.
Abbreviations: MRSA, methicillin-resistant Staphylcoccus aureus; OPD, outpatient departments.
Table 2 Multidrug resistance* in MRSA
Resistance to MRSA (n = 301)
More than three nonvancomycin 
antimicrobials
45.18% (136)
All antimicrobials except vancomycin 22.25% (67)
All antimicrobials except vancomycin 
and cefoperazone/sulbactam
4.31% (13)
All antimicrobials 0.033% (1)
Total multidrug resistance 72.1% (217)
Note: *MRSA strains which were resistant to three or more than three antibiotics 
tested were considered to be multidrug-resistant MRSA.
Abbreviation: MRSA, methicillin-resistant Staphylcoccus aureus.Infection and Drug Resistance 2008:1 60
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The MRSA strain that showed resistance to all 
antimicrobials including vancomycin was isolated from a 
56-year-old male patient admitted in post-operative ward of 
our hospital. The zone of inhibition shown by this strain in 
response to vancomycin disc was less than 9 mm; therefore we 
tentatively characterized this strain as vancomycin resistant 
S. aureus. Molecular investigation of the strain for the pres-
ence of vanA/B gene is needed to clarify its exact status.
Patterns of resistance shown by MRSA to Beta-lactams, 
aminoglycosides and quinolones are more or less identical 
in OPDs and wards, while the same to erythromycin, 
chloramphenicol, tetracycline, cotrimoxazole, nitrofurantoin, 
and betalactam/betalactamase inhibitor combination present 
certain level of difference between their distributions in 
OPDs and wards. This is a reﬂ  ection of differential drug 
pressure.
Currently, the majority (80%–90%) of S. aureus strains 
in communities are beta-lactamase producers hence resistant 
to penicillin and ampicillin (Paradisi et al 2001; Ang 2004). 
Recently more than 90% isolates from South Maharashtra 
have been found resistant to ampicillin, tobramycin, 
penicillin, erythromycin, kanamycin and gentamicin, 
whereas only 39.1% of strains are resistant to methicillin 
(Kandle et al 2003). The choice is obviously oxacillin; how-
ever, fearing MRSA, clinicians may exploit vancomycin. Our 
study reports that antibiotics other than vancomycin – for 
instance, amikacin, tobramycin, gentamicin, cefoperazone/
sulbactam – can be promising if a susceptibility testing is 
done, reserving vancomycin for life-threatening infections. 
A retrospective study of bacterial isolates from cases of neo-
natal septicemia over a period of ﬁ  ve years from Chandigarh, 
India, has also reported that netilmicin was the most effective 
drug for S. aureus (Agnihotri et al 2004).
Factors contributing to drug resistance in developing 
countries are myriad. Antibiotics are available without 
prescription at drug stores or even at general stores and 
injudiciously used in communities, animal husbandries, 
and ﬁ  sheries. Traditional practitioners use allopathic drugs, 
and many practitioners who earn by selling medicines pre-
scribe more drugs than necessary (Holloway 2000). In a 
study from ﬁ  ve districts of Tamilnadu, India, 285 general 
practitioners and specialists believed that antibiotics are over-
prescribed: purulent discharge (65%), antibiotic-resistance 
concerns (48%), fever (40%), and patient satisfaction (29%) 
being the strong reasons for overprescription (Sivagnanam 
et al 2004). Poor quality antibiotics are produced at local 
levels, and patients show poor compliance to costly 
antimicrobials (Hart 1998). Therefore, there is no other way 
than to foil these malpractices, to constantly conduct micro-
biological surveillance like this, and follow infection control 
measures like hand washing and other aseptic techniques if 
we are to avoid therapeutic crisis resulting from multidrug-
resistant MRSA.
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